Evaluating in vivo PARP-1 expression with 18F-FluorThanatrace positron emission tomography (PET/CT) in Pancreatic Cancer

This is a pilot study in patients with histologically proven pancreatic adenocarcinoma who have demonstrated at least stable disease following at least 16 weeks of treatment with platinum-based chemotherapy and are recommended for treatment with a PARP inhibitor with or without additional agents, either as part of their clinical care or another study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania. Patients who come to the University of Pennsylvania for diagnosis and/or treatment of pancreatic cancer and who meet the study inclusion criteria may be approached by study personnel for recruitment into this study. Patients will be approached about study participation regardless of race or ethnic background. We anticipate enrolling up to 30 participants. Accrual will likely occur over approximately 2-3 years. After undergoing screening assessments and verifying eligibility for study participation subjects will undergo an experimental [18F]FTT PET/CT scan. If a patient is going to biopsy then tumor tissue may be obtained for research purposes if there is enough tissue available for research. Patients may return for an optional second FTT PET/CT scan approximately 3 weeks after the start of PARP inhibitor therapy.

You may be eligible for this study if you meet the following criteria:

• Conditions: pancreatic cancer
• Age: 99 years or below
• Gender: All